Rhythm Pharmaceuticals (RYTM) revenue breakdown
By product, Product revenue, net is the largest at 100% of fiscal 2025 revenue, growing 1054% a year over 1 years.
By region, US is the largest at 74% of fiscal 2024 revenue; International grew fastest, 265% a year over 2 years.
Revenue by product
Fiscal years, as Rhythm Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $195M.
| Products | 2022 | 2025 | Share |
|---|---|---|---|
| Product revenue, net | $17M | $195M | 100% |
| License revenue | $7M | -$5M | -3% |
Revenue by region
Fiscal years, as Rhythm Pharmaceuticals reports them in its 10-K filings; fiscal 2024 total $130M.
| Regions | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|
| US | $21M | $62M | $96M | 74% |
| International | $3M | $15M | $34M | 26% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RYTM.
Open RYTM in InvestinglyQuestions
Where does Rhythm Pharmaceuticals make its money?
In fiscal 2025, by product: Product revenue, net $195M, License revenue -$5M.
From Rhythm Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.